Adefovir: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Adefovir" ([Edit=Allow only autoconfirmed users] (expires 15:51, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:51, 7 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox<!-- Drugbox data refers to adefovir, not adefovir dipivoxil. -->
__NOTOC__
| IUPAC_name = 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
{{Adefovir}}
| image = Adefovir.png
{{CMG}}
| width = 208
| CAS_number = 142340-99-6
| ATC_prefix = J05
| ATC_suffix = AF08
| ATC_supplemental =
| PubChem = 60172
| DrugBank = APRD00781
| C = 8 | H = 12 | N = 5 | O = 4 | P = 1
| molecular_weight = 273.186 g/mol
| bioavailability = 59%
| protein_bound =
| metabolism =
| elimination_half-life = 7.5 hours
| pregnancy_US = C
| legal_status = Rx-only
| routes_of_administration =
}}
[[Image:Adefovir dipivoxil.png|right|frame|Adefovir dipivoxil]]


'''Adefovir dipivoxil''', previously called '''bis-POM PMEA''', with trade names '''Preveon®''' and '''Hepsera®''', is an orally-administered nucleotide analog [[reverse transcriptase inhibitor]] (ntRTI) used for treatment of [[hepatitis B]]. It is a failed treatment for [[HIV]].
==Overview==


==History==
==Category==
Adefovir was invented in the Institute of Organic Chemistry and Biochemistry, [[Academy of Sciences of the Czech Republic]] by [[Antonín Holý]], and the drug was developed by [[Gilead Sciences]] for [[HIV]] with the brand name '''Preveon'''. However, in November 1999, an expert panel advised the U.S. [[Food and Drug Administration]] (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120&nbsp;mg. The FDA followed that advice, refusing to approve adefovir as a treatment for HIV.
Antiviral


[[Gilead Sciences]] discontinued its development for HIV treatment in December 1999 but continued to develop the drug for [[hepatitis B]] (HBV), where it is effective with a much lower dose of 10&nbsp;mg. FDA approval for use in the treatment of hepatitis B was granted on [[September 20]], [[2002]], and adefovir is sold for this indication under the brand name ''Hepsera''.
==US Brand Names==
HEPSERA<sup>®</sup>
==FDA Package Insert==
'''  [[Adefovir description|Description]]'''
'''| [[Adefovir clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Adefovir microbiology|Microbiology]]'''
'''| [[Adefovir indications and usage|Indications and Usage]]'''
'''| [[Adefovir contraindications|Contraindications]]'''
'''| [[Adefovir warnings and precautions|Warnings and Precautions]]'''
'''| [[Adefovir adverse reactions|Adverse Reactions]]'''
'''| [[Adefovir overdosage|Overdosage]]'''
'''| [[Adefovir clinical studies|Clinical Studies]]'''
'''| [[Adefovir dosage and administration|Dosage and Administration]]'''
'''| [[Adefovir compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[Adefovir directions for use|Directions For Use]]'''
'''| [[Adefovir how supplied|How Supplied]]'''
'''| [[Adefovir labels and packages|Labels and Packages]]'''


Adefovir became an approved treatment for HBV in the United States in September 2002 and in the European Union in March 2003.
==Mechanism of Action==


==Mechanism of action==
==References==
Adefovir works by blocking [[reverse transcriptase]], an enzyme that is crucial for the [[hepatitis B]] virus (HBV) to reproduce in the body.
{{Reflist|2}}


It is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum [[aminotransferase]]s (primarily ALT) or histologically active disease.
[[Category:Antiviral]]
 
[[Category:Wikinfect]]
The main benefit of adefovir over [[lamivudine]] (the first NRTI approved for the treatment of hepatitis B) is that it takes a much longer period of time before the virus develops resistance to it.
 
==External links==
 
*[http://www.hepsera.com Hepsera web site]
*{{PubChem|60172}} - Adefovir dipivoxil
 
{{Antivirals}}
[[Category:Gilead Sciences]]
[[Category:Antivirals]]
{{WikiDoc Help Menu}}

Revision as of 21:49, 1 January 2014

Adefovir
HEPSERA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Category

Antiviral

US Brand Names

HEPSERA®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Adefovir&oldid=922505"